At Zogenix, our core strategy is to commercialize and develop differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs and overcome limitations of existing products.

We are a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Our first commercial product, SUMAVEL^® DosePro™ (sumatriptan injection) Needle-free Delivery System, was launched in January 2010. SUMAVEL DosePro offers fast-acting, easy-to-use, needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache in a pre-filled, single-use delivery system. SUMAVEL DosePro is the first drug product approved by the FDA that allows for the needle-free, subcutaneous delivery of medication. Our lead product candidate, Zohydro (hydrocodone bitartrate) extended-release capsules (formerly ZX002), is a novel, oral, single-entity controlled-release formulation of hydrocodone currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. SUMAVEL DosePro and Zohydro each has the potential to address significant unmet medical needs and become important and widely-used additions to the treatment options available to patients and physicians in the United States' multi-billion dollar migraine and chronic pain markets, respectively.

Manufacturing
SUMAVEL^® DosePro™

A behind-the-scenes look of how SUMAVEL DosePro is manufactured. It delivers fast acting therapy that patients can self-administer in three easy steps. Watch the video

SUMAVEL^® DosePro™

SUMAVEL DosePro utilizes our proprietary DosePro needle-free drug delivery system to subcutaneously administer sumatriptan for the acute treatment of migraine and cluster headache. Sumavel DosePro is a fast acting therapy that patients can self-administer in three easy steps. Click here to learn more.

For full prescribing information, click here.